logo

For the Inventor, By the Inventor

Madison, CT, United States of America

James S New

This inventor holds 9 USPTO granted patents. Top assignees: Bristol-Myers Company, Mead Johnson & Company, Other. Active years: 1985-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James S New. Retrieved from https://idiyas.com/inventor/james-s-new

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 5

Forward Citations = 89(Granted Patents)


Location History:

  • Evansville, IN (US) (1985 - 1988)
  • Belle Mead, NJ (US) (1992)
  • Madison, CT (US) (1987 - 1993)

Company Filing History:

goldMedal4 out of 637 
 
Bristol-Myers Company
 patents
silverMedal1 out of 142 
 
Mead Johnson & Company
 patents
bronzeMedal4 out of 834,570 
Other
 patents

Years Active: 1985-1993

Loading Chart...
9 patents (USPTO):Explore Patents
1. 5206365 - Psychotropic heterobicycloalkylpiperazine derivatives (1993-04-27),
2. 5137894 - 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides (1992-08-11),
3. 5116970 - Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused (1992-05-26),
4. 5001130 - Psychotropic heterobicycloalkylpiperazine derivatives (1991-03-19),
5. 4880930 - Psychotropic acyclic amide derivatives (1989-11-14),
6. 4757073 - Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) (1988-07-12),
7. 4677104 - Antipsychotic fused-ring pyridinylpiperazine derivatives (1987-06-30),
8. 4619930 - Antipsychotic cyclic imide derivatives of (1986-10-28),
9. 4524206 - 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives (1985-06-18),

Title: Exploring the Inventive Mind of James S New

Introduction:

James S New, a distinguished inventor hailing from Madison, CT, has made significant contributions in the field of psychotropic medications with a total of 9 patents to his name. His innovative spirit and dedication to advancing pharmaceutical science have led to groundbreaking developments in the realm of antipsychotic and anxiolytic agents.

Latest Patents:

Among his latest patents stand out the creation of psychotropic heterobicycloalkylpiperazine derivatives, a novel series of compounds designed to act as potent antipsychotic and anxiolytic agents. These derivatives exhibit a unique structure that sets them apart in terms of efficacy and utility in treating mental health disorders. Additionally, James S New has patented 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides, showcasing his commitment to developing antipsychotic medications with reduced side-effect liability.

Career Highlights:

Throughout his illustrious career, James S New has garnered experience working with reputable companies such as Bristol-Myers Squibb, where he honed his skills and expanded his knowledge in the pharmaceutical industry. His journey as an inventor showcases a relentless pursuit of excellence and a passion for innovation that continues to drive his success in developing groundbreaking medications.

Collaborations:

James S New has collaborated with esteemed colleagues such as Joseph P Yevich and William L Christopher, both of whom have played integral roles in shaping the landscape of psychotropic drug development. Their combined expertise and innovative approaches have paved the way for pioneering advancements in the field, demonstrating the power of teamwork in driving scientific progress.

Conclusion:

In conclusion, James S New stands as a visionary inventor whose inventive prowess has led to the creation of groundbreaking psychotropic medications. His dedication to excellence, coupled with his collaborative spirit, underscores his commitment to advancing pharmaceutical science for the betterment of human health. James S New's contributions serve as a testament to the profound impact that inventors can have on society through their relentless pursuit of innovation and discovery.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…